Category Archives: People

CVC Credit Partners appoints Nick Haaijman to its investor relations team

Haaijman joins as Head of Client Services, based in London

CVC Credit Partners is pleased to announce that Nick Haaijman has joined its investor relations team as a Managing Director and Head of Client Services. He is based in CVC’s London office and reports to Mike Anderson, CVC Credit Partners’ Head of Investor Relations.

Nick joined from Alcentra, where he spent more than 10 years in the Business Development team in London, latterly as Global Head of Product Management. He joined Alcentra in 2008 from J.P.Morgan, where he worked in the Structured Credit Product Management team. Nick holds a Master of Science Business Administration from Vrije Universiteit, Amsterdam.

Mike Anderson, Head of Investor Relations at CVC Credit Partners, said: “I am very pleased to welcome Nick to our investor relations team. With the growth of the business over the past few years, we are working closer than ever with our investor base, to help them access global credit markets and at the same time, continually looking to enhance their investor experience across our various credit funds. Nick’s wealth of experience in product development and client services will be extremely valuable as we continue to build a best-in-class investor relations team.”

Nick Haaijman added: “I am delighted to be joining CVC Credit Partners, a leading alternative credit manager with an outstanding reputation and performance. This is an ambitious business and I very much look forward to working with Mike and his team to continue to deliver a first-rate investor experience and to drive us towards our full potential.”

Categories: People

Pantheon Announces Senior Strategic Appointments

Pantheon

Chief Technology Officer at Partner level

Global Head of Recruitment

In recognition of the accelerating complexity of operating a robust global private markets firm, Pantheon announces two significant and senior appointments. John Eggleston joins as Partner and Chief Technology Officer, while Richard Berke joins as Global Head of Recruitment, a new position. Both bring outstanding credentials and track records in their specialist fields.The appointments demonstrate the priority and vigilance that Pantheon places on attracting strong talent to lead and innovate important functions. Pantheon has recruited over 125 new permanent professionals across its global teams through 2018 and 2019 to date, evidence of the need for a seasoned recruitment specialist to oversee and implement a best-in-class resourcing infrastructure.John Eggleston, whose impressive technology career stretches back to 1996, joins from BGF plc, a £2.5 billion investment company where he was a member of the Executive & Investment Committees. John led the TMT investment group as well as being a non-exec Director on several Boards and providing strategic CTO support to many companies in the portfolio. Prior to BGF, John was co-founding Chief Information Officer at Callcredit, which grew from initial concept to acquisition by TransUnion for over $1bn. At Pantheon, John has oversight responsibility for core technology infrastructure, information security and systems development. Richard Berke brings nearly two decades of financial services recruitment experience with him, most recently from Insight Investment where Richard was Head of Resourcing. Earlier this year, Pantheon appointed Charlotte Tallon as Head of HR for the Americas. Charlotte joined from Barclays where she was HR Business Partner, and she is based in Pantheon’s New York office.“We are delighted to have such highly talented professionals join us in strategically important positions,” said Paul Ward, Managing Partner. “Our operating model continues to experience fast change – we carry a responsibility to be both alert and responsive to that challenge. Technology and people are two vital elements on which the security and success of the whole firm depends. Accordingly, Pantheon’s Board prioritizes and invests in ensuring Pantheon is resourced appropriately in terms of seniority, skill and experience.” John Eggleston reports to Robin Bailey, Chief Operating Officer. Richard Berke reports to Dianne Remanous, Global Head of HR. Both are based in Pantheon’s London office. Photographs and interviews are available on request.Ends.

PRESS RELEASE

Connect with us

Notes to Editors For further information,

please contact: Pantheon Amanda McCrystal, Global Head of Marketing and Communications Tel: +44 20 3356 1718 | C: +44 7557 233771 | Email: amanda.mccrystal@pantheon.com

About Pantheon

Pantheon Group* (“Pantheon”) is a leading global private equity, infrastructure, real assets and debt fund investor that invests on behalf of over 585 investors, including public and private pension plans, insurance companies, endowments and foundations. Founded in 1982, Pantheon has developed an established reputation in primary, co-investment and secondary private asset solutions across all stages and geographies. Our investment solutions include customized separate account programs, regional primary fund programs, secondaries, co-investment, infrastructure and real assets programs. Pantheon has four decades’ experience of investing in private markets. As at March 31st, 2019 Pantheon had $46.3 billion assets under management** and we currently have around 310 employees located across our offices in London, San Francisco, New York, Hong Kong, Seoul***, Bogotá***, Tokyo and Dublin. Our employees include 94 investment professionals. Pantheon is majority-owned by Affiliated Managers Group Inc. (“AMG”), alongside senior members of the Pantheon team. AMG is a NYSE-listed global asset management company with equity investments in leading boutique investment management firms. The ownership structure, with Pantheon management owning a meaningful share of the equity in the business, provides a framework for long-term succession and enables Pantheon management to continue to direct the firm’s day-to-day operations. * Pantheon Group refers to the subsidiaries and subsidiary undertakings of Pantheon Ventures Inc. and AMG Plymouth UK Holdings Limited and includes operating entities principally based in the US (San Francisco and New York), UK (London), Hong Kong, Guernsey and Dublin. Pantheon Ventures Inc. and Pantheon Ventures (US) LP are registered as investment advisors with the U.S. Securities and Exchange Commission (“SEC”); Pantheon Securities, LLC. is a broker dealer registered with the SEC and is a member of the Financial Industry Regulatory Authority (“FINRA”).

Pantheon Ventures (UK) LLP is authorised and regulated by the Financial Conduct Authority (“FCA”) in the United Kingdom. Pantheon Ventures (HK) LLP is regulated by the Securities and Futures Commission in Hong Kong. Pantheon Ventures (Guernsey) Ltd and a number of other Pantheon entities incorporated in Guernsey are regulated by the Guernsey Financial Services Commission. Pantheon Ventures (Asia) Limited is registered as a Type II Financial Instruments Business and Investment Advisory and Agency Business Operator with the Kanto Local Finance Bureau in Japan (KLFB). ** This figure includes assets subject to discretionary or non-discretionary management, advice or those limited to a reporting function. Data is unaudited. *** Please note that the Bogotá office is a representative office of Pantheon Ventures (US) LP (“PV US”), and that a Korean subsidiary of PV US has opened the office in Seoul.

This press release is not an offer of securities for sale. Securities may not be offered or sold in the United States absent registration or an exemption from registration. © 2019

Categories: People

Kinly announces Robbert Bakker as new CEO

Avedon

Amsterdam, NETHERLANDS – Monday 30th September 2019, 13:00 CET – Kinly, The leading specialist in video collaboration solutions – announced today that Robbert Bakker has been named as their new CEO.

KinlyFeaturedPRRobbert, previously CEO of Knab, the Dutch online-only bank, has an outstanding track record of executive management positions across several of Kinly’s key target verticals. He has a background in digital transformation and high growth companies, which along with his experience in building organizations with Customer Focus engraved in the DNA of its people makes him the perfect candidate to join Kinly on its journey to become the leader in its industry.

“I have seen how video collaboration is changing the way we work, and I am impressed with how Kinly’s services address this transformation. We are truly solving a growing need, and I want to be part of that journey, also for the positive environmental aspects of it,” says Robbert Bakker. “The values and culture of the company are well aligned with my own, and I look forward to contributing in this regard too.”

Jos Zandhuis, Chairman of the Board in Kinly, said, “Robbert Bakker has a very strong and proven track record both as an executive, a leader and an innovator. We believe he is perfectly positioned to take Kinly to the next level. He will have full support from very competent teams of employees around the world. Kinly has already grown in revenue almost 50% over the last year and a half, and there is still a large potential for further growth as a specialist in collaboration services”

Robbert Bakker will formally join Kinly on September 30th and will be based at the company headquarters in Amsterdam. In addition to the announcement of the new CEO, Kinly would also like to announce that Mike Gries will be its new Managing Director and SVP of the Netherlands, joining the Kinly Team on October 1st.

Categories: People

The Carlyle Group Names John Kim as Managing Director of Asia Buyout Team

Carlyle

Seoul – Global alternative asset manager The Carlyle Group (NASDAQ: CG) today announced that John Kim will join the firm as a Managing Director of the Asia Buyout Team effective March 2020. Mr. Kim will lead Carlyle’s investment activities in Korea.

Joining from Goldman Sachs, where he served as Head of Mergers & Acquisitions in Asia ex-Japan, John brings more than 20 years’ experience in the financial industry. He previously served as the bank’s Co-Country Head of Korea and Head of Investment Banking in Korea and joined the firm in 2000 as an Executive Director for Corporate Finance in Seoul.

X.D. Yang, Managing Director and Chairman of Carlyle Asia, said, “John is an experienced leader in the region and has a wide range of experience working on significant transactions throughout Asia. We believe his background and deep understanding of the Korean market will help us position the business for the future and continue to create value for all of our stakeholders in the region.”

Greg Zeluck, Co-Head of the Asia Buyout team, said, “John joins at an exciting time for Carlyle in Korea. We see compelling opportunities, driven by restructurings within the corporate sector, multinationals and chaebols looking to divest non-core businesses, and generational changes. John will be a strong addition to the team as we continue to increase our investment in Korea.”

The Carlyle Group was one of the first global investment firms to establish a presence in Korea, having operated in the country for 20 years. As of June 30, 2019, the firm has invested more than US$1.5 billion of equity in Korea. Among the firm’s most recent and notable transactions has been its investment in ADT Caps, Korea’s second largest security services provider, and Yakjin Trading Corp, a major Korean apparel manufacturer.

About The Carlyle Group

The Carlyle Group (NASDAQ: CG) is a global investment firm with deep industry expertise that deploys private capital across four business segments: Corporate Private Equity, Real Assets, Global Credit and Investment Solutions. With $223 billion of assets under management as of June 30, 2019, Carlyle’s purpose is to invest wisely and create value on behalf of its investors, portfolio companies and the communities in which we live and invest. The Carlyle Group employs more than 1,775 people in 33 offices across six continents.

Web: www.carlyle.com

 

Media Contact:

The Carlyle Group
Tammy Li
Phone: +852 2878 5236
Email: tammy.li@carlyle.com

Categories: People

Kinnevik appoints Erika Söderberg Johnson as Chief Financial Officer

Kinnevik

1 Oct, 2019, 08:00 AM · Regulatory information

Kinnevik AB (publ) (“Kinnevik”), today announced that it has appointed Erika Söderberg Johnson as Chief Financial Officer. Erika Söderberg Johnson joins Kinnevik from Biotage where she has been CFO since 2012 and she will take up her position at the latest on 6 April 2020.

Georgi Ganev, CEO of Kinnevik, commented, “I am very pleased to welcome Erika to Kinnevik. She brings a wealth of experience including working as a CFO in fast growing listed medtech businesses, board work in Saab and Qliro Group and deep understanding of corporate finance from her early career in investment banking. I am confident that she will be a great addition to Kinnevik’s management team and add valuable insights to our portfolio companies.“

Prior to joining Biotage, Erika Söderberg Johnson was Chief Financial Officer at Karo Bio (2007-2011), Affibody (2005-2007) and Global Genomics (2002-2005) and she has been a board member of Sectra AB and MedCap AB. Erika Söderberg Johnson also worked ten years in Investment Banking and Corporate Finance at SEB Enskilda. She is a board member of publicly listed companies Saab AB (since 2017) and Qliro Group AB (since 2017). Erika Söderberg Johnson was born in 1970 and has a M.Sc. BA from Stockholm School of Economics.

For further information, visit www.kinnevik.com or contact:

Torun Litzén, Director Investor Relations
Phone +46 (0)70 762 00 50
Email press@kinnevik.com

Kinnevik is an industry focused investment company with an entrepreneurial spirit. Our purpose is to build the digital consumer businesses that provide more and better choice. We do this by working in partnership with talented founders and management teams to create, invest in and lead fast growing businesses in developed and emerging markets. We believe in delivering both shareholder and social value by building well governed companies that contribute positively to society. Kinnevik was founded in 1936 by the Stenbeck, Klingspor and von Horn families. Kinnevik’s shares are listed on Nasdaq Stockholm’s list for large cap companies under the ticker codes KINV A and KINV B.

Categories: People

Dyne Therapeutics announces appointment of Joshua Brumm as President and Chief Executive Office

Forbion

in portfolio news

Industry veteran brings extensive experience leading biotech companies through periods of growth.

WALTHAM, Mass.– Dyne Therapeutics, a biotechnology company pioneering targeted therapies for patients with serious muscle diseases, today announced the appointment of Joshua Brumm as President and Chief Executive Officer.

“Josh brings extraordinary skills and experience to further our mission of creating life-transforming therapies for patients with serious muscle diseases,” said Jason Rhodes, partner with Atlas Venture and Dyne founder and executive chairman of the board of directors. “This positions us strongly to pursue the next phase of growth and product development, and we are thrilled to have him joining us.”

“Dyne’s FORCE therapeutic platform achieves a unique combination of tissue-specific delivery, high potency and tolerability to enable a broad product pipeline,” said Joshua Brumm. “I look forward to working closely with the board and talented team at Dyne to maximize the potential of our platform by advancing our pipeline and exploring new partnerships.”
“On behalf of everyone here, I am excited to welcome Josh,” said Romesh Subramanian, Dyne founder and chief scientific officer. “We look forward to working together to realize the therapeutic power of oligonucleotides for patients with rare muscle diseases and fulfilling Dyne’s mission.”

Prior to joining Dyne, Mr. Brumm served as chief operating officer and chief financial officer of Kaleido Biosciences, where he led the company’s financings including its initial public offering and helped bring the lead program into Phase 2 development. Prior to joining Kaleido, Mr. Brumm was COO and CFO at Versartis, where he oversaw the company’s financial strategy including the successful completion of its IPO, played an integral role in product strategy, and helped negotiate the company’s first product partnership. His previous roles include serving as executive vice president of finance and principal financial officer at Pharmacyclics; CFO at ZELTIQ Aesthetics, where he led the company through its initial public offering, led the international product launch for CoolSculpting and also served in corporate development; and director of finance at Proteolix, Inc., assisting in the sale of the company to Onyx Pharmaceuticals. He also held investment banking roles at Citigroup Global Markets, Inc. and Morgan Stanley. Over the course of his career, Mr. Brumm has raised approximately $1 billion in capital. In 2014, he was named Silicon Valley Business Journal’s CFO of the Year for companies under $500 million. He holds a B.A. in business administration from the University of Notre Dame.

About Dyne Therapeutics
Dyne Therapeutics is pioneering life-transforming therapies for patients with serious muscle diseases. The company’s FORCE™ platform delivers oligonucleotides and other molecules to skeletal, cardiac and smooth muscle with unprecedented precision to restore muscle health. Dyne is advancing treatments for myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD), and facioscapulohumeral muscular dystrophy (FSHD). Dyne was founded in 2018 and is based in Waltham, Mass.

For more information, please visit www.dyne-tx.com.
Media Contact Ten Bridge Communications Max Stendahl, 508-277-8117 max@tenbridgecommunications.com

Categories: People

Tags:

Avedon Capital Partners expands team with appointment of Willem van der Veer

Avedon

Categories: People

Apiary Capital appoints new Investment Manager

Apiary Capital

Team-Jess.jpg

Apiary Capital is pleased to announce the appointment of Jessica French as Investment Manager.

Jess joins Apiary from boutique investment bank, Financo, having previously spent eight years at PwC, primarily in Corporate Finance advisory.

Jess’s appointment follows the successful close of Apiary’s £200m maiden fund last year, and the subsequent completion of the G3 Comms, Connect and Bertram Nursery Group investments earlier this year.

Mark Salter, Managing Partner at Apiary Capital commented, “Jess’s addition provides depth and breadth to our investment capability and we are delighted to welcome her to the Apiary team.”

Categories: People

n2 Biomedical Appoints Victor Nunes and Dean Schauer to Board of Directors

Bedford, MA – September 30, 2019: N2 Biomedical, a leading provider of proprietary surface treatment solutions and nanoscale coatings for implantable medical devices, today announced the appointments of Victor (“Vic”) Nunes and Dean Schauer to the Company’s Board of Directors. Nunes and Schauer join the Board following Ampersand Capital Partners’ majority recapitalization of the Company earlier this year. The transaction with Ampersand provided N2 Biomedical with an equity investment to fuel organic growth, expand the Company’s capabilities, and increase commercial sales efforts.

Mr. Nunes has over 25 years of medical device industry experience. He has served in a number of senior management and advisory roles in various medical device and life sciences companies, with a particular emphasis on orthopedics. Previous experience includes a variety of roles within DePuy Orthopedics, where he led integration of the $21 billion Synthes acquisition and assisted in the integration of DePuy Ace into Johnson & Johnson. Mr. Nunes also held Board positions at the Depuy Mitek and Codman Neuro divisions of J&J during his tenure as Senior Operations Executive. He has received advanced certifications from Duke University, the University of Virginia, and the University of Pennsylvania.

Mr. Schauer has served as President and CEO of Ampersand portfolio company Confluent Medical Technologies since 2013, and also joined Ampersand as an Operating Partner in 2016. Prior to Confluent, Mr. Schauer held a variety of executive leadership roles at Accellent, and was most recently Executive Vice President and General Manager of Accellent’s Cardiovascular Business. Prior roles at Accellent and its predecessors included EVP of Operations and Engineering, EVP of Sales and Marketing, and VP of Quality. Mr. Schauer holds a B.S. in Metallurgical Engineering from South Dakota Tech and is trained in Six Sigma methodology.

“Both Vic and Dean are proven, experienced executives within the medical device industry, and bring valuable insight to N2’s evolving growth strategy,” said Randall Sword, CEO of N2 Biomedical. “The additions to our Board come at an exciting time for N2 as we look to expand our service offering within medical end-markets. We welcome Vic and Dean’s experiences and guidance as we continue to build N2.”

About N2 Biomedical

Established in 2013, N2 provides coating and surface treatment development and application services for implantable and other medical devices utilized in orthopedic, cardiovascular, and other healthcare end-markets. N2 is ISO-13485 certified, FDA GMP-compliant, and operates in a 30,000 square foot facility with laboratory, manufacturing, and cleanroom space to service all customer and regulatory requirements. The company leverages its proprietary processes and equipment to provide customized solutions that enhance the characteristics of various materials in critical applications, including lubricity, infection resistance, biocompatibility and tissue integration, and wear and corrosion resistance. Additional information about N2 Biomedical is available at N2bio.com.

About Ampersand Capital Partners

Founded in 1988, Ampersand is a middle market private equity firm dedicated to growth-oriented investments in the healthcare sector. With offices in Boston, MA and Amsterdam, Netherlands, Ampersand leverages a unique blend of private equity and operating experience to build value and drive superior long-term performance alongside its portfolio company management teams. Ampersand has helped build numerous market-leading companies across each of its core healthcare sectors, including Avista Pharma Solutions, Brammer Bio, Confluent Medical, Genewiz, Genoptix, Talecris Biotherapeutics, and Viracor-IBT Laboratories. Additional information about Ampersand is available at ampersandcapital.com.

Categories: People

The Carlyle Group Names Matt Anderson Chief Digital Officer and Stefan Grunwald Chief Procurement Officer

Carlyle

WASHINGTON – Global investment firm The Carlyle Group (NASDAQ: CG) today announced it has appointed two executives focused on driving value across its global portfolio. Matt Anderson, former President and Chief Digital Officer at Arrow Electronics, has been named Carlyle’s first Chief Digital Officer, and Stefan Grunwald, former Senior Vice President of Strategic Sourcing and Procurement at Cardinal Health, has been named Carlyle’s Chief Procurement Officer, effective today.

Both executives will deliver strategic and operational support to Carlyle’s portfolio companies and investment teams, working with the firm’s investment professionals and advisors including its Operating Executive and Senior Advisor consultants.

Anderson will develop and implement digital transformation strategies to help the firms in which Carlyle has invested grow and assist Carlyle’s investment teams in finding such opportunities during the diligence process. He will identify and execute new strategies in digital, data and analytics and other technologies, build an ecosystem of experts and suppliers, and play a leading role in CEO mentorship.

Grunwald will serve as the procurement and supply chain specialist for Carlyle’s portfolio and collaborate with management teams to identify and implement procurement and supply chain efficiency improvements. In addition, he will work with Carlyle’s investment teams to uncover procurement opportunities during due diligence.

Peter J. Clare, Co-Chief Investment Officer at The Carlyle Group, said, “The addition of Matt and Stefan to the Carlyle team underscores our commitment to creating value through operational improvement and to providing management teams with unrivaled tools and resources to grow.”

Clare continued, “With a proven track record of identifying and growing digital business opportunities, Matt is the right choice to help us find new, technology-driven ways to create near- and long-term impact. Stefan, an accomplished executive with 30 years of experience, will play an important role in helping our companies uncover value creation opportunities across their supply chains.”

Anderson said, “Carlyle’s growth-oriented investment approach is zeroing in on digital tools and resources as an important differentiator for its companies to unlock value, efficiencies and new business models. I look forward to partnering with some of the world’s most talented management teams, and to being part of the value-add that Carlyle brings to its investments.”

Grunwald said, “I am delighted to join Carlyle’s collaborative team and look forward to working closely with colleagues across the globe to facilitate procurement capabilities that generate positive results.”

Anderson, based in New York, brings a wealth of experience in both advising on and delivering digital transformations across a range of industries. Prior to Carlyle, he led the expansion of electronic components and computer products maker Arrow Electronics’ digital business. He led Arrow’s innovative partnership with Indiegogo, its expansion into cloud technology distribution, and launched an “on demand” engineering platform for high-tech design in the B2B space. Prior to Arrow, he led Booz & Co’s eCommerce and digitization practice and developed its digital transformation agency model before developing a digital business at UK-based yellow page and internet services company Hibu, formerly Yell Group. He holds Bachelor of Arts degrees in Economics and International Relations from the University of Pennsylvania.

Grunwald, based in Washington, D.C., brings a strong background leading enterprise-wide procurement transformations and managing teams from diverse functional and cultural backgrounds. Prior to Carlyle, he served as Senior Vice President of Strategic Sourcing and Procurement at healthcare services company Cardinal Health where he was accountable for Cardinal’s $10 billion Medical Device spend. Prior to that, he spent 19 years at Whirlpool Corporation in various leadership roles during which he managed teams in China, Brazil, Sweden and Italy. He holds a Bachelor of Science degree in Aerospace Engineering from Syracuse University.

* * * * *

About The Carlyle Group
The Carlyle Group (NASDAQ: CG) is a global investment firm with deep industry expertise that deploys private capital across four business segments: Corporate Private Equity, Real Assets, Global Credit and Investment Solutions. With $223 billion of assets under management as of June 30, 2019, Carlyle’s purpose is to invest wisely and create value on behalf of its investors, portfolio companies and the communities in which we live and invest. The Carlyle Group employs more than 1,775 people in 33 offices across six continents.

Contact
Christa Zipf
+1 (212) 813-4578
christa.zipf@carlyle.com

Categories: People